Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer:: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up

Trial 24, one of three ongoing trials in the Early Prostate Cancer programme, is evaluating the efficacy and tolerability of bicalutamide ( Casodex) 150mg following standard care (radiotherapy, radical prostatectomy or watchful waiting) in patients with early, non-metastatic prostate cancer. At 7 years' median follow-up, addition of bicalutamide significantly improved objective progression-free survival (PFS) for patients with locally advanced disease, reducing the risk of progression by 34% versus standard care alone ( hazard ratio 0.66; 95% confidence interval 0.55, 0.79; P < 0.001). In localized disease, a significant difference in objective PFS was not found. There was no significant difference in overall survival.